By Kamya Elawadhi, Co-founder and President, Doceree
LinkedIn: Kamya Elawadhi
LinkedIn: Doceree
When did “we believe we reached physicians” become an acceptable standard for a billion-dollar industry? Somewhere along the way, pharma marketing made peace with probabilistic targeting, inferred identities, and impression counts that looked impressive but proved little. The industry didn’t lower its clinical standards. It just never applied them to its media buying.
That disconnect is no longer sustainable. And it’s not a media buying problem. It’s a structural one.
The Illusion of Efficiency
Programmatic advertising promised healthcare marketers the world: automation, scale, precision. For general consumer marketing, it largely delivered. But healthcare is not general consumer marketing. Healthcare professionals are not casual browsers waiting to be retargeted with a reminder about something they once Googled. They are credentialed, time-pressed clinicians operating within highly specific professional workflows, and they have extraordinarily little patience for irrelevant noise.
Yet for years, the dominant approach to reaching HCPs programmatically borrowed the same logic used to sell sneakers: buy impressions cheaply, cast wide, optimize for clicks. I’ve watched brands pour significant budget into campaigns that technically “reached” physicians and generated almost no behavioral signal in return. The result has been a quiet epidemic of wasted spend ads served to unverified audiences, in generic digital environments, stripped of any clinical context, and measured by metrics that have little to do with actual behavior change.
The industry has spent years perfecting the wrong model.
The Problem Isn’t Programmatic. It’s Programmatic Without Standards.
To be clear: programmatic as a delivery mechanism is not the issue. The ability to reach the right person, at the right moment, with a precisely tailored message at scale — is still one of the most powerful capabilities available to healthcare marketers. The failure has been in how that capability has been deployed.
Standard programmatic infrastructure was built for open web audiences, cookie-based targeting, and high-volume impression trading. Layering healthcare audiences on top of that architecture is like performing microsurgery with a blunt instrument. It was never designed for this level of precision, and the results reflect it.
The data make the opportunity cost impossible to ignore. On average, HCPs spend 84% of their weekly time consuming medical information through digital resources, with dedicated professional platforms, clinical journal websites, and physician networks accounting for the bulk of that time. That is an enormous concentration of professional attention, and most programmatic buying strategies are nowhere near it. We have known this for years. The infrastructure to act on it has simply lagged behind.
What pharma brands are increasingly recognizing, and what we’ve seen proven repeatedly, is that reaching HCPs demands infrastructure built from the ground up for the healthcare context. Verified professional identity at the point of targeting, not probabilistic lookalike modeling. Placement within the clinical environments where HCPs actually spend their professional digital time, in medical journals, specialty platforms, research databases, not open web adjacencies that happen to share a demographic profile. And contextual intelligence that understands the clinical moment: what condition is being researched, what therapeutic area is in focus, what decision might be forming.
When a nephrologist is reading a clinical review on SGLT2 inhibitors in CKD, the ad environment is doing something a general publisher simply cannot replicate. The message lands differently. It becomes part of a professional thought process rather than an interruption of a personal one.
The Ownership Question the Industry Can No Longer Defer
Here is what should be unsettling for anyone responsible for HCP marketing budgets: most organizations still don’t actually know whether their programmatic impressions are reaching licensed, on-target physicians. They have modeled audiences, inferred identities, and probabilistic targeting segments, but not verified reach. In a category where a single prescriber’s behavior can drive millions in revenue, that ambiguity is not a performance issue. It is a strategic failure.
The relevance gap compounds it. A 2024 industry survey found that 68% of HCPs say they ignore communications unless the content feels personally relevant, a figure that should alarm any marketer still relying on broad-based targeting and generic creative. Relevance is not a nice-to-have. It is the minimum entry requirement for HCP attention. And it cannot be engineered from a general audience segment. It requires clinical context, endemic placement, and identity precision working in concert.
The shift toward premium programmatic frameworks addresses this directly. Deterministic identity resolution, matching against verified NPI-level data, changes the accountability structure of the entire campaign. Marketers move from “we believe these impressions reached cardiologists” to “these specific, verified cardiologists were reached, and here is how their prescribing behavior shifted.” That is not a marginal improvement. It is a categorical one. Script lift analysis, NPI-level reporting, and behavioral signal tracking after exposure allow brands to draw a direct line between media investment and clinical outcome, the kind of accountability that brand leaders, market access teams, and finance partners are no longer willing to do without.
The Window for Competitive Advantage Is Narrowing
The broader digital advertising ecosystem is in flux. Third-party cookies are eroding. Privacy regulations are tightening. HCPs are more discerning than ever about where their attention goes. The brands building durable HCP relationships today are doing so inside clinical ecosystems, not by chasing the cheapest CPM available on the open web.
Premium programmatic is not a luxury tier of the same old approach. It is a fundamental rethinking of what programmatic must mean in a healthcare context: verified reach, endemic environments, clinical context, adaptable formats, and rigorous measurement working as an integrated system, not a collection of disconnected tools.
The marketers who recognize this now will have a meaningful head start. The ones who wait are already behind.